The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620774
Title:
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.
Authors:
Forker, Laura-Jane; Gaunt, P; Sioletic, S; Shenjere, Patrick; Potter, Robert; Roberts, Darren L; Irlam, Joely J; Valentine, Helen R; Hughes, D; Hughes, A; Billingham, L; Grimer, R; Seddon, B; Choudhury, Ananya ( 0000-0002-3561-6580 ) ; Robinson, M; West, Catharine M L ( 0000-0002-0839-3449 )
Abstract:
Despite high metastasis rates, adjuvant/neoadjuvant systemic therapy for localised soft tissue sarcoma (STS) is not used routinely. Progress requires tailoring therapy to features of tumour biology, which need exploration in well-documented cohorts. Hypoxia has been linked to metastasis in STS and is targetable. This study evaluated hypoxia prognostic markers in the phase III adjuvant radiotherapy VorteX trial.
Affiliation:
Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX
Citation:
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. 2017 Br J Cancer
Journal:
British Journal of Cancer
Issue Date:
12-Dec-2017
URI:
http://hdl.handle.net/10541/620774
DOI:
10.1038/bjc.2017.430
PubMed ID:
29235571
Type:
Article
Language:
en
ISSN:
1532-1827
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorForker, Laura-Janeen
dc.contributor.authorGaunt, Pen
dc.contributor.authorSioletic, Sen
dc.contributor.authorShenjere, Patricken
dc.contributor.authorPotter, Roberten
dc.contributor.authorRoberts, Darren Len
dc.contributor.authorIrlam, Joely Jen
dc.contributor.authorValentine, Helen Ren
dc.contributor.authorHughes, Den
dc.contributor.authorHughes, Aen
dc.contributor.authorBillingham, Len
dc.contributor.authorGrimer, Ren
dc.contributor.authorSeddon, Ben
dc.contributor.authorChoudhury, Ananyaen
dc.contributor.authorRobinson, Men
dc.contributor.authorWest, Catharine M Len
dc.date.accessioned2018-01-12T09:22:23Z-
dc.date.available2018-01-12T09:22:23Z-
dc.date.issued2017-12-12-
dc.identifier.citationThe hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. 2017 Br J Canceren
dc.identifier.issn1532-1827-
dc.identifier.pmid29235571-
dc.identifier.doi10.1038/bjc.2017.430-
dc.identifier.urihttp://hdl.handle.net/10541/620774-
dc.description.abstractDespite high metastasis rates, adjuvant/neoadjuvant systemic therapy for localised soft tissue sarcoma (STS) is not used routinely. Progress requires tailoring therapy to features of tumour biology, which need exploration in well-documented cohorts. Hypoxia has been linked to metastasis in STS and is targetable. This study evaluated hypoxia prognostic markers in the phase III adjuvant radiotherapy VorteX trial.en
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleThe hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.en
dc.typeArticleen
dc.contributor.departmentTranslational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BXen
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.